Prils Market Analysis

  • Report ID: 4109
  • Published Date: Nov 21, 2025
  • Report Format: PDF, PPT

Prils Market Segmentation:

Application (Hypertension, Heart Failure, Chronic Kidney Disorder)

The hypertension segment is estimated to hold 50% share of the global prils market in the year 2035. The growth of the segment can be attributed to the increasing cases of hypertension across the globe. As more individuals with hypertension may need medications to control their blood pressure, this could lead to an increase in demand for market.

Besides prils are frequently combined with other antihypertensive drugs to improve blood pressure control which is further expected to contribute to the market growth. Around 970 million people worldwide, or over 25% of the population, have hypertension, and by 2025, that number is projected to rise by over 28%.

Distribution Channel (Hospital, Pharmacies)

Prils market from the hospital segment is expected to garner a significant share of 40% in the year 2035. Prils may be prescribed in hospitals for patients with comorbidities, such as diabetes or chronic renal disease that are frequently linked to hypertension or heart failure. They may be provided as part of the therapy plan for various comorbidities since many individuals admitted to hospitals may have several medical problems. As a result, the demand for prils in hospitals may be expanding along with the prevalence of these comorbidities. As a consequence, multiple opportunities for the segment's growth are expected in the next years.

Our in-depth analysis of the global prils market includes the following segments:

           Type

  • Amipril

  • Quinapril

  • Cilazapril

  • Benazepril

          Distribution Channel 

  • Hospital

  • Pharmacies

            Application

  • Hypertension

  • Heart Failure

  • Chronic Kidney Disorder

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of prils is evaluated at USD 2.65 billion.

The global prils market size was worth more than USD 2.51 billion in 2025 and is poised to witness a CAGR of over 6.4%, crossing USD 4.67 billion revenue by 2035.

North America is anticipated to command a 41% share of the Prils Market by 2035, owing to the increasing cases of obesity.

Key players in the market include Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos